Who is at risk?
Every treatment decision counts—especially when it comes to reducing the risk of recurrence.
of recurrence.1
These real-world data come from a retrospective study using the US nationwide Flatiron Health EHR-derived de-identified database. Patients with HR+, HER2−, node-positive, EBC who underwent breast cancer surgery and then initiated adjuvant ET-based therapy from January 2023 to March 2024 were selected (N=3170). High-risk N1/N1mi disease was defined as Grade 3 or a tumor ≥5 cm. Adjuvant CDK4/6i treatment was assessed from January 2023 through June 2024. Baseline characteristics were summarized descriptively and included nodal status, age, race/ethnicity, insurance, socioeconomic status, and practice setting.1
Results are based on a post hoc subgroup analysis, following the methodology used by Sheffield, et al (2022).2 This analysis was exploratory and did not test a hypothesis.1,2
Reasons for prescribing or not prescribing CDK4/6 inhibitors to eligible patients are not available in the Flatiron Health database. It is unknown which disease characteristics were accessible or considered when making treatment decisions. The Flatiron Health database does not capture comorbidities, financial considerations, or patient and physician discussion.1
WHAT IS THE RISK?
Undertreating patients may mean recurrence isn’t just possible—it’s more likely1,3
Patients with high-risk features are more than 2x as likely to experience recurrence vs patients without those features3
- Risk of recurrence is highest in the first 2 years following primary treatment2
Throughout my whole
ALLEGRA, a real patient diagnosed with HR+, HER2−, high-risk EBC
treatment, I shared I don’t
want to wait for a recurrence.
I want a chance to keep
pursuing my love of travel for
as long as possible.
Your Privacy Choices